Citations

Mayo Clinic

Clear

509 citation(s) found for "Ma, Ping".

Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization
Dai, Haiming , Smith, Alyson , Meng, X. Wei, Schneider, Paula A., Pang, Yuan‐Ping , Kaufmann, Scott H. , Kaufmann, Scott H , Pang, Yuan-Ping , Dai, Haiming

Journal of Cell Biology | July 4, 2011 | Volume: 194 | Issue: 1 | Pages: 39-48

10.1083/jcb.201102027 | PMID 21727192 Get It

The mechanism by which the proapoptotic Bcl-2 family members Bax and Bak release cytochrome c from mitochondria is incompletely understood. In this paper, we show that activator BH3-only proteins bind tightly but transiently to the Bak hydrophobic BH3-binding groove to induce Bak oligomerization, liposome permeabilization, mitochondrial cytochrome c release, and cell death. Analysis by surface plasmon resonance indicated that the initial binding of BH3-only proteins to Bak occurred with similar kinetics with or without detergent or mitochondrial lipids, but these reagents increase the strength of the Bak–BH3-only protein interaction. Point mutations in Bak and reciprocal mutations in the BH3-only proteins not only confirmed the identity of the interacting residues at the Bak–BH3-only protein interface but also demonstrated specificity of complex formation in vitro and in a cellular context. These observations indicate that transient protein–protein interactions involving the Bak BH3-binding groove initiate Bak oligomerization and activation.
Genetic Variations in Multiple Drug Action Pathways and Survival in Advanced Stage Non–Small Cell Lung Cancer Treated with Chemotherapy
Li, Yafei , Sun, Zhifu , Cunningham, Julie M. , Aubry, Marie Christine, Wampfler, Jason A. , Croghan, Gary A., Johnson, Cassandra, Wu, Danli, Aakre, Jeremiah A. , Molina, Julian R. , Wang, Liewei , Pankratz, V. Shane , Yang, Ping , Sun, Zhifu

Clinical Cancer Research | June 3, 2011 | Volume: 17 | Issue: 11 | Pages: 3830-3840

10.1158/1078-0432.ccr-10-2877 | PMID 21636554 Get It

Abstract Purpose: Variations in genes related to biological activity of anticancer drugs could influence treatment responses and lung cancer prognosis. Genetic variants in four biological pathways, that is, glutathione metabolism, DNA repair, cell cycle, and epidermal growth factor receptor (EGFR), were systematically investigated to examine their association with survival in advanced stage non–small cell lung cancer (NSCLC) treated with chemotherapy. Experimental Design: A total of 894 tagging single-nucleotide polymorphisms (SNP) in 70 genes from the four pathways were genotyped and analyzed in a 1,076-patient cohort. Association with overall survival was analyzed at SNP and whole-gene levels within all patients and major chemotherapy agent combination groups. Results: A poorer overall survival was observed in patients with genetic variations in GSS (glutathione pathway) and MAP3K1 (EGFR pathway; HR = 1.45; 95% CI = 1.20–1.77 and HR = 1.25; 95% CI = 1.05–1.50, respectively). In the stratified analysis on patients receiving platinum plus taxane treatment, we observed a hazardous effect on overall survival by the MAP3K1 variant (HR = 1.38; 95% CI = 1.11–1.72) and a protective effect by RAF1 (HR = 0.64; 95% CI = 0.50–0.82) in the EGFR pathway. In patients receiving platinum plus gemcitabine treatment, RAF1 and GPX5 (glutathione pathway) genetic variations showed protective effects on survival (HR = 0.54; 95% CI = 0.38–0.77; HR = 0.67; 95% CI = 0.52–0.85, respectively); in contrast, NRAS (EGFR pathway) and GPX7 (glutathione pathway) variations showed hazardous effects on overall survival (HR = 1.91; 95% CI = 1.30–2.80; HR = 1.83; 95% CI = 1.27–2.63, respectively). All genes that harbored these significant SNPs remained significant by whole-gene analysis. Conclusion: Common genetic variations in genes of EGFR and glutathione pathways may be associated with overall survival among patients with advanced stage NSCLC treated with platinum, taxane, and/or gemicitabine combinations. Clin Cancer Res; 17(11); 3830–40. ©2011 AACR.
Abstract P4-03-01: Inhibition of Fatty Acid Synthase (FASN) Sensitizes Breast Cancer Cells to Chemotherapy and Disrupts the Lipid Rafts
Hong, Ping , Busby, Robert C. , Ruth, L., Espinoza, Ignacio

Cancer Research | April 27, 2011 | Volume: 70 | Issue: 24_Supplement | Pages: P4-03-01-P4-03-01

10.1158/0008-5472.sabcs10-p4-03-01 Get It

Abstract MN Background: Breast cancer is the second leading cause of cancer death of women worldwide. One of the major challenges for a better prognosis of breast cancer patients is the ineffectiveness of chemotherapy and drug resistance. To investigate the mechanisms of drug resistance, resistant cancer cell lines have been established with various anticancer agents. We found that FASN, an important metabolic enzyme overexpressed in aggressive carcinomas, is t responsible in part for the drug resistance phenotype of breast cancer cells. Our findings show that blockage of FASN augments the cytotoxicity of the anti-mitotic drug Taxol in breast cancer cells. Moreover, C75 and Taxol have a synergistic effect both drugs are combined. The in vivo effect of C75 and Taxol and the mechanism by which blockage of FASN sensitizes the cells to chemotherapy are unknown. Material and Methods: In this study first we show the effect of C75 plus Taxol in breast tumor growth. BT474 cells were injected into the mammary fat pad of nude mice to generate the tumors. When the tumors were measurable we treated the mice with C75, Taxol or with a combination of both drugs. Second we studied the lipid rafts disruption after treatments by sucrose gradient and immunofluorescence. Results: We found that C75 plus Taxol extensively inhibited the tumor growth 9 fold and reduced the tumor size in 4 fold comparedn to the control mice (no treatement). In comparison C75 alone reduced the tumor growth in 1.5 fold only; and Taxol 2.5 fold compared to the control mice. These results show for first time that blockage of FASN (with C75) sensitizes breast cancer tumors to Taxol treatment in vivo. In addition, we studied the possible mechanism involved in the sensitization of breast cancer cells to Taxol by FASN blockage. Previous studies reported that blockage of FASN or Taxol treatment decrease the sphingolipids synthesis. Sphingolipids and cholesterol are the most abundant fatty acid in the lipid rafts in the plasma membrane. Disruption of lipid rafts has been shown to induce apoptosis in different carcinoma cell lines. Based in these findings, we studied lipid rafts in BT474 cells treated with C75, Taxol or combination of both with sucrose gradient and immunofluorescence microscopy. Discussion: Our results show that C75 and Taxol disrupt the lipid rafts. Thesefindings show that FASN is a new mechanism of drug resistance and may be an ideal target for chemosensitization in breast cancer chemotherapy. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-03-01.
Prospective Study of Breast Cancer Incidence in Women With a BRCA1 or BRCA2 Mutation Under Surveillance With and Without Magnetic Resonance Imaging
Hill, Kimberley, Causer, Petrina A., Plewes, Donald B., Jong, Roberta A., Yaffe, Martin J. , Foulkes, William D. , Ghadirian, Parviz, Lynch, Henry T., Wright, Frances C. , Sun, Ping , Narod, Steven A. , Warner, Ellen , Couch, Fergus J. , Wong, John W. , Foulkes, William D

Journal of Clinical Oncology | March 29, 2011 | Volume: 29 | Issue: 13 | Pages: 1664-1669

10.1200/jco.2009.27.0835 | PMID 21444874 Get It

Purpose The sensitivity of magnetic resonance imaging (MRI) for breast cancer screening exceeds that of mammography. If MRI screening reduces mortality in women with a BRCA1 or BRCA2 mutation, it is expected that the incidence of advanced-stage breast cancers should be reduced in women undergoing MRI screening compared with those undergoing conventional screening. Patients and Methods We followed 1,275 women with a BRCA1 or BRCA2 mutation for a mean of 3.2 years. In total, 445 women were enrolled in an MRI screening trial in Toronto, Ontario, Canada, and 830 were in the comparison group. The cumulative incidences of ductal carcinoma in situ (DCIS), early-stage, and late-stage breast cancers were estimated at 6 years in the cohorts. Results There were 41 cases of breast cancer in the MRI-screened cohort (9.2%) and 76 cases in the comparison group (9.2%). The cumulative incidence of DCIS or stage I breast cancer at 6 years was 13.8% (95% CI, 9.1% to 18.5%) in the MRI-screened cohort and 7.2% (95% CI, 4.5% to 9.9%) in the comparison group (P = .01). The cumulative incidence of stages II to IV breast cancers was 1.9% (95% CI, 0.2% to 3.7%) in the MRI-screened cohort and 6.6% (95% CI, 3.8% to 9.3%) in the comparison group (P = .02). The adjusted hazard ratio for the development of stages II to IV breast cancer associated with MRI screening was 0.30 (95% CI, 0.12 to 0.72; P = .008). Conclusion Annual surveillance with MRI is associated with a significant reduction in the incidence of advanced-stage breast cancer in BRCA1 and BRCA2 carriers.
Scavenger receptor CD36 is essential for the cerebrovascular oxidative stress and neurovascular dysfunction induced by amyloid-β
Park, Laibaik , Zhou, Ping , Zhou, Joan, Pitstick, Rose, Previti, Mary Lou , Younkin, Linda H., Younkin, Steven G. , Nostrand, William E. Van , Anrather, Josef , Carlson, George A. , Iadecola, Costantino , Wang, Gang , Cho, Sunghee

Proceedings of the National Academy of Sciences | March 8, 2011 | Volume: 108 | Issue: 12 | Pages: 5063-5068

10.1073/pnas.1015413108 | PMID 21383152 Get It

Increasing evidence indicates that cerebrovascular dysfunction plays a pathogenic role in Alzheimer's dementia (AD). Amyloid-β (Aβ), a peptide central to the pathogenesis of AD, has profound vascular effects mediated, for the most part, by reactive oxygen species produced by the enzyme NADPH oxidase. The mechanisms linking Aβ to NADPH oxidase-dependent vascular oxidative stress have not been identified, however. We report that the scavenger receptor CD36, a membrane glycoprotein that binds Aβ, is essential for the vascular oxidative stress and neurovascular dysfunction induced by Aβ 1–40 . Thus, topical application of Aβ 1–40 onto the somatosensory cortex attenuates the increase in cerebral blood flow elicited by neural activity or by endothelium-dependent vasodilators in WT mice but not in CD36-null mice (CD36 0/0 ). The cerebrovascular effects of infusion of Aβ 1–40 into cerebral arteries are not observed in mice pretreated with CD36 blocking antibodies or in CD36 0/0 mice. Furthermore, CD36 deficiency prevents the neurovascular dysfunction observed in transgenic mice overexpressing the Swedish mutation of the amyloid precursor protein Tg2576 despite elevated levels of brain Aβ 1–40 . CD36 is also required for the vascular oxidative stress induced by exogenous Aβ 1–40 or observed in Tg2576 mice. These observations establish CD36 as a key link between Aβ 1–40 and the NADPH oxidase-dependent vascular oxidative stress underlying the neurovascular dysfunction and suggest that CD36 is a potential therapeutical target to counteract the cerebrovascular dysfunction associated with Aβ.
Abstract LB-186: Genetic variants and risk of lung cancer in never-smokers: A genome-wide association study
Ye, Yuanqing , Chang, Shen‐Chih , Aubry, Marie‐Christine, Aakre, Jeremiah A. , Cunningham, Julie M. , Deschamps, Claude, Jiang, Ruoxiang , Lin, Jie , Marks, Randolph, Su, Li , Vasmatzis, George , Wang, Renyi , Harris, Curtis C. , Spitz, Margaret R., Jen, Jin , Wu, Xifeng , Li, Yafei , Sheu, Chau‐Chyun , Andrade, Mariza de , Wang, Liang , Allen, Mark S. , Chen, Feng , Pankratz, V. Shane , Li, Yan , Sun, Zhifu , Tang, Hui Jun , Zhang, Zuo‐Feng , Christiani, David C. , Yang, Ping

Cancer Research | February 25, 2011 | Volume: 70 | Issue: 8_Supplement | Pages: LB-186-LB-186

10.1158/1538-7445.am10-lb-186 Get It

Abstract Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-186.
Abstract 4826: International Lung Cancer Consortium: Pooled analysis of previous lung diseases and lung cancer risk
Brenner, Darren R. , Bickeböller, Heike , Wichmann, Erich, Schwartz, Ann G. , Friis, Søren, Field, John K. , McLaughlin, John R., Lan, Qing , Park, Bernard J. , Hung, Rayjean J., Boffetta, Paolo , Duell, Eric J. , Rosenberger, Albert , Muscat, Joshua E. , Yang, Ping , Tjønneland, Anne , Marchand, Loı̈c Le , Zhang, Zuo‐Feng , Lazarus, Philip J. , McLaughlin, John R., Wiencke, John K. , Neri, Monica , Orlow, Irene , Hung, Rayjean J., Field, John K , Bickeböller, Heike

Cancer Research | February 25, 2011 | Volume: 70 | Issue: 8_Supplement | Pages: 4826-4826

10.1158/1538-7445.am10-4826 Get It

Abstract To clarify the role of previous lung diseases (PLDs) (chronic bronchitis, emphysema, pneumonia, tuberculosis, asbestosis and silicosis) in the development of lung cancer we conducted a pooled analysis in the International Lung Cancer Consortium (ILCCO). Data from 16 studies (9 population based case-control, 4 hospital based case-control, 2 mixed case-control and 1 cohort - 10 from North America, 5 from Europe and 1 from Asia) were pooled, including 24044 cases and 81256 controls. Study-specific effect estimates were derived using logistic regression models for case-control studies and Cox proportional hazards models for cohort studies adjusted for age, sex, education and pack-years of smoking. Effect estimates were then pooled using random effects models where summary effects for each of the PLDs were evaluated separately. Stratified analyses were conducted based on smoking status, histology and study design or control source. Heterogeneity was evaluated using the Cochrane Q statistic and Galbraith plots, and publication bias was evaluated using funnel plots as well as the Begg test. A previous history of emphysema conferred a relative risk (RR) of 2.17, 95% confidence interval (CI): 1.67-2.82 (from 15 studies, p-het<.001). A previous history of chronic bronchitis conferred a RR of 1.49, 95% CI: 1.33-1.60 (from 12 studies, p-het.=0.434). Tuberculosis was associated with a RR of 1.54, 95% CI: 1.19-1.99 (from 15 studies, p-het.=0.001). Both asbestosis (RR 2.51, 95% CI: 1.53-4.12 (from 7 studies, p-het=0.379)) and silicosis (RR 1.70, 95% CI: 1.15-2.54, (from 3 studies, p-het. p=0.476)) were also associated with lung cancer risk. When the outlying studies were removed, effect estimates changed minimally and heterogeneity was reduced. Findings were consistent in subgroup analyses by smoking status and histology (adenocarcinoma, squamous cell carcinoma and small cell lung cancer). Effect estimates among never smokers were for emphysema a RR of 2.21, 95% CI: 0.99-4.90 (from 8 studies), for chronic bronchitis 1.12, 95% CI: 0.78-1.62 (from 9 studies), for pneumonia 1.37, 95% CI: 1.10-1.70 (from 10 studies) and for tuberculosis 1.54, 95% CI: 0.99-2.39 (from 9 studies). In this analysis of data from multiple continents, PLDs were associated with an increased risk of lung cancer. The evidence among never smokers supports a direct relationship between previous lung diseases and lung cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4826.
Ordered Subset Analysis Identifies Loci Influencing Lung Cancer Risk on Chromosomes 6q and 12q
Fang, Shenying , Pinney, Susan M. , Bailey‐Wilson, Joan E. , Andrade, Mariza A. de, Li, Yafang , Kupert, Elena, You, Ming, Schwartz, Ann G. , Anderson, Marshall W., Yang, Ping , Amos, Christopher I. , Wilson, Richard K , Pinney, Susan M

Cancer Epidemiology, Biomarkers & Prevention | December 14, 2010 | Volume: 19 | Issue: 12 | Pages: 3157-3166

10.1158/1055-9965.epi-10-0792 | PMID 21030603 Get It

Abstract Background: Genetic susceptibility for cancer can differ substantially among families. We use trait-related covariates to identify a genetically homogeneous subset of families with the best evidence for linkage in the presence of heterogeneity. Methods: We performed a genome-wide linkage screen in 93 families. Samples and data were collected by the familial lung cancer recruitment sites of the Genetic Epidemiology of Lung Cancer Consortium. We estimated linkage scores for each family by the Markov chain Monte Carlo procedure using SimWalk2 software. We used ordered subset analysis (OSA) to identify genetically homogenous families by ordering families based on a disease-associated covariate. We performed permutation tests to determine the relationship between the trait-related covariate and the evidence for linkage. Results: A genome-wide screen for lung cancer loci identified strong evidence for linkage to 6q23–25 and suggestive evidence for linkage to 12q24 using OSA, with peak logarithm of odds (LOD) scores of 4.19 and 2.79, respectively. We found other chromosomes also suggestive for linkages, including 5q31–q33, 14q11, and 16q24. Conclusions: Our OSA results support 6q as a lung cancer susceptibility locus and provide evidence for disease linkage on 12q24. This study further increased our understanding of the inheritability for lung cancer. Validation studies using larger sample size are needed to verify the presence of several other chromosomal regions suggestive of an increased risk for lung cancer and/or other cancers. Impact: OSA can reduce genetic heterogeneity in linkage study and may assist in revealing novel susceptibility loci. Cancer Epidemiol Biomarkers Prev; 19(12); 3157–66. ©2010 AACR.
Effect of Emphysema on Lung Cancer Risk in Smokers: A Computed Tomography–Based Assessment
Li, Yan , Swensen, Stephen J., Karabekmez, Leman Günbey , Marks, Randolph S., Stoddard, Shawn M., Jiang, Ruoxiang , Worra, Joel B., Zhang, Fang , Midthun, David E. , Song, Yong , Andrade, Mariza de , Yang, Ping

Cancer Prevention Research | December 1, 2010 | Volume: 4 | Issue: 1 | Pages: 43-50

10.1158/1940-6207.capr-10-0151 | PMID 21119049 Get It

Abstract The contribution of emphysema to lung cancer risk has been recognized, but the effect size needs to be further defined. In this study, 565 primary lung cancer cases were enrolled though a prospective lung cancer cohort at Mayo Clinic, and 450 controls were smokers participating in a lung cancer screening study in the same institution using spiral computed tomography (CT). Cases and controls were frequency matched on age, gender, race, smoking status, and residential region. CT imaging using standard protocol at the time of lung cancer diagnosis (case) or during the study (control) was assessed for emphysema by visual scoring CT analysis as a percentage of lung tissue destroyed. The clinical definition of emphysema was the diagnosis recorded in the medical documentation. Using multiple logistic regression models, emphysema (≥5% on CT) was found to be associated with a 3.8-fold increased lung cancer risk in Caucasians, with higher risk in subgroups of younger (<65 years old, OR = 4.64), heavy smokers (≥40 pack-years, OR = 4.46), and small-cell lung cancer (OR = 5.62). When using >0% or ≥10% emphysema on CT, lung cancer risk was 2.79-fold or 3.33-fold higher than controls. Compared with CT evaluation (using criterion ≥5%), the sensitivity, specificity, positive and negative predictive values, and the accuracy of the clinical diagnosis for emphysema in controls were 19%, 98%, 73%, 84%, and 83%, respectively. These results imply that an accurate evaluation of emphysema could help reliably identify individuals at greater risk of lung cancer among smokers. Cancer Prev Res; 4(1); 43–50. ©2010 AACR.
Ankle Stability in Simulated Lateral Ankle Ligament Injuries
Fujii, Tadashi , Kitaoka, Harold B. , Watanabe, Kota , Luo, Zong-Ping , An, Kai‐Nan

Foot & Ankle International | June 18, 2010 | Volume: 31 | Issue: 6 | Pages: 531-537

10.3113/fai.2010.0531 | PMID 20557820 Get It

Background: We performed a laboratory-based study of the ankle-hindfoot complex in normal cadaveric ankles with simulated lateral ankle ligament injuries, utilizing an ankle stability testing device. The ankle stability testing device distinguished between intact, injury to anterior talofibular ligament (ATFL) and combined injury to ATFL and calcaneofibular ligament (CFL). Materials and Methods: Ankles were tested in an ankle stability testing device, with a specified inversion torque applied through the range of sagittal plane motion, then internal rotation torque applied through the entire range of sagittal plane motion. Three-dimensional motion of the calcaneus and talus in relation to the tibia were determined with a magnetic tracking system. The specimens were tested in the intact condition, then after sectioning the ATFL, then the CFL. Results: Upon sectioning the ATFL, there was a significant increase in the internal rotation motion at the tibiotalar joint. Subsequent sectioning of the CFL did not significantly increase ankle-hindfoot internal rotation, but it did significantly increase the motion in inversion testing. This increase occurred primarily at the tibiotalar level. Conclusion: The isolated ATFL injury was clearly distinguished from the intact condition by increased talar-tibial internal rotation, but not inversion. The more severe combined ATFL/CFL injury was distinguished from the ATFL injury condition with inversion torque. Clinical Relevance: Inversion torque may disclose combined ATFL/CFL injury, and internal rotation torque may be the key to distinguish isolated ATFL and combined ATFL/CFL injuries.